AGMB
AgomAb Therapeutics NV
NASDAQ · Healthcare · Biotechnology · BE
$8.23
−0.60%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -57.8%
Three-year CAGR
- Revenue
- —
- EBITDA
- -35.7%
- EBIT
- -23.4%
- Net income
- -35.2%
- EPS
- -1.6%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025